Innovative Bispecific Nanobody Targeting CD38 and CD3 Complex for Next-Generation Cancer Immunotherapy

VHH-P382 is an advanced humanized nanobody therapeutic candidate currently in the Biological Testing stage, engineered to target both the CD38 molecule (CD38) and the CD3 Complex (T Cell Receptor Complex). This bispecific antibody fusion leverages single-domain antibody technology, offering the potential for highly selective and potent therapeutic action in the treatment of cancer. By simultaneously engaging CD38 and CD3 Complex, VHH-P382 is designed to recruit and activate immune effector mechanisms against malignant cells. The program represents an innovative approach in cancer immunotherapy, aiming to address significant unmet needs in oncology with improved target specificity and therapeutic efficacy.

Licensing Opportunity

VHH-P382 is available for out-licensing and collaborative development opportunities. We welcome inquiries from biopharmaceutical partners interested in advancing this innovative nanobody-based immunotherapeutic toward clinical translation and commercialization.

Development Phase

Modality

VHH-P382 utilizes a symmetric bispecific antibody fusion format, featuring four anti-CD38 single-domain antibodies (nanobodies) attached via a6GS linkers to the N-terminus of each variable heavy and light chain of a humanized anti-CD3 monoclonal IgG1 kappa backbone, incorporating mutations in the Fc region for optimized function. The nanobody (VHH) architecture confers advantages such as small molecular size, high tissue penetration, and robust stability, making it highly suitable for solid tumor and hematologic malignancy applications. This structural design enhances its capacity to simultaneously bind CD38 and CD3 Complex, increasing the likelihood of effective tumor cell recognition and immune synapse formation, thereby resulting in more precise cancer targeting and activation of anti-tumor immunity.

Target

CD38 and CD3 Complex are both crucial molecular targets in oncology. CD38 is a transmembrane glycoprotein highly expressed on malignant plasma cells and various hematological cancer cells, as well as on some immune cells. The CD3 Complex is a multi-chain signaling module found on the surface of T cells, essential for T cell receptor-mediated signal transduction. By targeting CD38, VHH-P382 can selectively engage cancer cells, while interaction with CD3 Complex enables potent T cell redirection and activation. Both CD38 and CD3 Complex have emerged as validated targets for cancer immunotherapies due to their roles in tumor cell survival and immune regulation. The dual targeting strategy of VHH-P382 delivers exceptional tumor selectivity and offers a strategic asset for immune-mediated cancer treatment through concurrent CD38 and CD3 Complex engagement.

Mechanism of Action

VHH-P382 exerts its anti-cancer effects by concurrently binding to CD38 on malignant cells and CD3 Complex on T lymphocytes. This bispecific engagement leads to the formation of an immunological synapse, facilitating targeted T cell activation and redirection toward tumor cells expressing CD38. Through modulation of signal transduction pathways, VHH-P382 promotes immune cell-mediated lysis of cancer cells. The use of nanobody-based components provides distinctive advantages in avidity and tissue penetration. The molecular format of VHH-P382 is modular, supporting further therapeutic innovation, including development as an antibody–drug conjugate (ADC) or as a scaffold for additional bispecific or multispecific constructs engineered to address diverse oncological indications.

Cancer

Cancer remains one of the world’s most significant public health challenges, with high incidence and mortality globally across all major demographic groups. The spectrum of cancer includes solid tumors and hematologic malignancies, each posing different clinical complexities. Standard-of-care therapies such as surgery, radiation, chemotherapy, and targeted therapies have improved outcomes but are limited by resistance, toxicity, and incomplete tumor eradication. Immunotherapies, including T cell engagers and bispecific antibodies, are transforming the landscape, yet many patients still fail to achieve durable remissions, highlighting substantial unmet medical needs. The unique design of VHH-P382, which targets both cancer cell markers (CD38) and T cell activators (CD3 Complex), positions it as a promising next-generation immunotherapy candidate. Its ability to potentiate immune cell redirection and overcome tumor immune evasion may lead to improved response rates and survival outcomes for diverse cancer patient populations.